Waystar Holding Corp. Common Stock
WAY
$23.18
+2.02%
Waystar Holding Corp. is a provider of mission-critical cloud technology that streamlines healthcare payment processes for providers, payers, and patients. As a specialized platform company in the healthcare IT sector, it differentiates itself by automating complex revenue cycle workflows to enhance data integrity and accelerate reimbursement. The current investor narrative centers on the company's robust revenue growth trajectory, with the most recent quarter showing 24.4% YoY revenue expansion, while the stock has experienced significant price volatility since its IPO in June 2024, raising debates about valuation sustainability and market positioning.…
WAY
Waystar Holding Corp. Common Stock
$23.18
Investment Opinion: Should I buy WAY Today?
Rating: Buy. Thesis: Waystar's accelerating revenue growth, improving profitability, and deeply discounted forward P/E of 12.7x relative to industry peers create a compelling risk/reward for investors with a 12-month horizon. The analyst consensus is Strong Buy with an average target implying 42.6% upside. Supporting evidence: (1) Revenue grew 24.4% YoY to $303.5 million in Q4 2025, accelerating from 20.4% in Q4 2024. (2) Operating margin improved to 25.0% from 21.8% a year ago, showing operating leverage. (3) Forward P/E of 12.7x is well below the industry average of 20x, suggesting undervaluation relative to growth. (4) TTM free cash flow of $283.2 million provides a FCF yield of 4.5%, supporting intrinsic value. Risks & Conditions: The biggest risks are gross margin compression (down 1100 bps YoY), high trailing P/E (52x), and the stock's persistent downtrend. This Buy rating would be downgraded to Hold if revenue growth falls below 15% or if gross margins drop below 50%. It would be upgraded to Strong Buy if the stock breaks above its 50-day moving average and maintains 20%+ revenue growth. Overall, the stock appears undervalued on forward earnings and sales relative to its growth trajectory, but the trailing metrics suggest caution.
Sign up to view all
WAY 12-Month Price Forecast
Waystar's fundamentals are strong, with accelerating revenue growth and improving profitability. The forward valuation is attractive, trading at a discount to peers on a P/E basis. However, the stock's technical downtrend and gross margin compression warrant caution. The base case of 20-25% growth and moderate margin expansion is most likely, supporting a target of $28-$33. If the company can stabilize gross margins and deliver on earnings expectations, the stock could re-rate higher. Key catalysts to watch are the next earnings report and any large contract wins. The stance is bullish but with medium confidence due to the stock's recent price action and margin risks.
Wall Street consensus
The stock is covered by 5 analysts, with a consensus leaning bullish. All recent ratings from major firms (Deutsche Bank, Wells Fargo, Truist, Evercore, BMO, Barclays, Goldman Sachs, Canaccord, Citigroup) are Buy or Outperform, with one upgrade from Hold to Buy by Freedom Capital Markets. The average EPS estimate for the next fiscal year is $2.635, and the average revenue estimate is $1.85 billion. Based on the forward P/E of 12.70x and current price of $23.46, the implied target price is approximately $33.46 (12.70 * $2.635), suggesting +42.6% upside. The consensus recommendation is Strong Buy, indicating strong bullish sentiment. The target range is not explicitly provided, but the EPS estimates range from $2.59 to $2.74, implying a price range of $32.88 to $34.80 based on the forward P/E. The high target assumes continued strong revenue growth and margin expansion, while the low target may factor in competitive pressures or slower adoption. The wide spread in EPS estimates (5.9% range) suggests moderate uncertainty. The recent upgrade by Freedom Capital Markets from Hold to Buy indicates improving sentiment. Overall, the analyst community is highly optimistic about Waystar's growth prospects, but the limited number of analysts (5) suggests it is still a relatively small-cap or newly public company, which can lead to higher volatility and less efficient price discovery.
Drowning in data?
Find the real signal!
Bulls vs Bears: WAY Investment Factors
Waystar presents a classic growth-at-a-reasonable-price (GARP) debate. On the bull side, the company is delivering strong revenue growth (24.4% YoY), improving operating margins, and a forward P/E of 12.7x that suggests significant upside if earnings materialize. The balance sheet is healthy with moderate debt and positive free cash flow. On the bear side, the stock has been in a sustained downtrend, losing nearly 40% over the past year, and the trailing P/E of 52x is expensive relative to peers. Gross margin compression and low ROE raise questions about competitive positioning and capital efficiency. The single most important tension is whether the company can deliver the aggressive earnings growth implied by the forward P/E—if it does, the stock is deeply undervalued; if it falters, further multiple compression could drive the stock to new lows. Currently, the bull case has stronger evidence given the accelerating revenue and analyst consensus, but the bearish price action demands caution.
Bullish
- Strong Revenue Growth: Revenue grew 24.4% YoY in Q4 2025 to $303.5 million, accelerating from prior quarters. This indicates strong market adoption and potential share gains in healthcare payments technology.
- Improving Profitability: Operating margin improved to 25.0% in Q4 2025 from 21.8% a year ago, demonstrating operating leverage. Net income was positive for four consecutive quarters, with TTM net income of $112.1 million.
- Attractive Forward Valuation: Forward P/E of 12.7x is well below the industry average of 20x, implying significant earnings growth. Based on average EPS estimate of $2.635, the implied target price is $33.46, offering 42.6% upside from $23.46.
- Healthy Balance Sheet: Debt-to-equity ratio is 0.39, indicating moderate leverage, and current ratio of 1.41 suggests adequate liquidity. TTM free cash flow of $283.2 million provides a FCF yield of ~4.5%.
Bearish
- Massive Stock Decline: Stock is down 39.3% over the past year and trades at 56.6% of its 52-week range. The 52-week low of $17.26 was tested in May 2026, indicating persistent bearish momentum.
- High Trailing P/E: Trailing P/E of 52.0x is more than double the industry median of ~25x, reflecting a 108% premium. This leaves little room for error if growth disappoints.
- Margin Compression: Gross margin declined to 56.2% in Q4 2025 from 67.4% a year ago, a drop of over 1100 basis points. This could signal increased competition or cost pressures.
- Low ROE and Beta: ROE is only 2.9%, indicating low return on shareholder equity. Beta of 0.07 is unusually low for a tech stock, possibly reflecting limited liquidity or an atypical risk profile.
WAY Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -39.33% and currently trading at 56.6% of its 52-week range (price $23.46 vs. 52w low $17.26 and high $41.47). This positioning near the lower end of the range suggests a potential value opportunity, but the persistent decline indicates bearish sentiment and possible further downside risk. The 52-week low of $17.26 was recently tested in May 2026, and the stock has since bounced, but remains well below the midpoint of the range. Short-term momentum shows a conflicting signal: the 1-month price change is +12.68%, while the 3-month change is -1.18%, indicating a recent recovery attempt within a longer-term downtrend. This divergence could signal a potential trend reversal or a temporary pullback, especially as the 1-month gain contrasts with the 1-year decline. The RSI is not provided, but the recent price action from $17.31 on June 22 to $23.46 on July 2 suggests a sharp rally, which may be overextended in the short term. Key support is at the 52-week low of $17.26, while resistance is at the 52-week high of $41.47. A breakout above $41.47 would signal a major trend reversal, while a breakdown below $17.26 could lead to further declines. The stock's beta of 0.07 indicates extremely low volatility relative to the market, meaning it moves much less than the S&P 500, which is unusual for a technology stock and may reflect limited trading liquidity or a unique risk profile.
Beta
0.07
0.07x market volatility
Max Drawdown
-57.9%
Largest decline past year
52-Week Range
$17-$41
Price range past year
Annual Return
-38.8%
Cumulative gain past year
| Period | WAY Return | S&P 500 |
|---|---|---|
| 1m | +20.9% | +2.0% |
| 3m | +7.8% | +10.6% |
| 6m | -32.8% | +8.3% |
| 1y | -38.8% | +20.4% |
| ytd | -26.1% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAY Fundamental Analysis
Revenue is growing strongly, with the most recent quarter (Q4 2025) reporting $303.5 million, up 24.4% YoY from $244.1 million in Q4 2024. The multi-quarter trend shows accelerating growth: Q1 2025 revenue was $256.4 million, Q2 $270.7 million, Q3 $268.7 million, and Q4 $303.5 million, indicating a sequential acceleration in the second half of the year. The primary revenue driver is subscription and circulation, which contributed $167.8 million in the most recent period, though segment data is limited. This growth trajectory supports the investment case for a company gaining market share in healthcare payments technology. The company is profitable, with net income of $20.0 million in Q4 2025, up from $19.1 million in Q4 2024, and a net margin of 6.6%. Gross margin was 56.2% in Q4 2025, down from 67.4% in Q4 2024, indicating some margin compression likely due to higher cost of revenue. Operating margin improved to 25.0% from 21.8% a year ago, suggesting better operating leverage. The company has been consistently profitable over the last four quarters, with net income ranging from $29.3 million to $32.2 million in the first three quarters of 2025. The balance sheet is healthy: debt-to-equity ratio is 0.39, indicating moderate leverage, and the current ratio is 1.41, suggesting adequate liquidity. Free cash flow (FCF) was $57.2 million in Q4 2025, and trailing twelve-month FCF is $283.2 million, implying a FCF yield of approximately 4.5% based on the current market cap of $6.27 billion. ROE is 2.9%, which is low but improving from negative levels in 2024. The company generates sufficient cash to fund operations, but the negative net change in cash of -$368.5 million in Q4 2025 was driven by large acquisition spending of $629.5 million, indicating reliance on external financing for growth investments.
Quarterly Revenue
$303538000.0B
2025-12
Revenue YoY Growth
+24.3%
YoY Comparison
Gross Margin
56.2%
Latest Quarter
Free Cash Flow
$283192000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAY Overvalued?
Since net income is positive (TTM net income of $112.1 million), the primary valuation metric is the P/E ratio. The trailing P/E is 51.98x, while the forward P/E is 12.70x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests that earnings are expected to more than quadruple in the next year, which is aggressive but may be justified by the company's growth trajectory. Compared to the industry average (Information Technology Services), the stock trades at a premium: the trailing P/E of 51.98x is well above the sector median of around 25x, representing a 108% premium. However, the forward P/E of 12.70x is below the industry average of 20x, indicating that the market is pricing in substantial earnings growth. This premium may be justified by the company's strong revenue growth and improving profitability, but it also implies high expectations. Historically, the stock's P/E has ranged from negative (when unprofitable) to over 80x in late 2024. The current trailing P/E of 51.98x is near the lower end of its historical range since profitability, suggesting that the valuation has compressed from higher levels. The P/S ratio of 5.70x is also below its historical average of around 20x, indicating that the stock is cheaper on a sales basis than in the past, which could signal a value opportunity if growth persists.
PE
52.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 54x~83x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company's trailing P/E of 52.0x leaves it vulnerable to earnings disappointments. While revenue is growing at 24.4%, gross margin compression from 67.4% to 56.2% YoY signals potential cost inflation or pricing pressure. The low ROE of 2.9% suggests inefficient use of equity capital, and the negative net change in cash of -$368.5 million in Q4 2025 due to large acquisitions indicates that growth investments are consuming cash, potentially straining liquidity if debt markets tighten. Market & Competitive Risks: The stock's beta of 0.07 is extremely low for a technology company, which may reflect limited trading liquidity or a unique risk profile that could lead to sharp moves on news. The stock trades at a 108% premium to the industry on trailing P/E, making it susceptible to valuation compression if growth decelerates or if sector rotation favors value stocks. The healthcare IT space is competitive, with larger players like Epic and Cerner, and any loss of key clients could materially impact revenue. Worst-Case Scenario: If revenue growth decelerates below 15% due to competitive losses or macro headwinds, and margins continue to compress, the stock could retest its 52-week low of $17.26. From the current price of $23.46, this represents a downside of -26.4%. In a severe recession or if the company issues a major earnings miss, the stock could fall to $15, implying a -36% loss. The historical max drawdown of -57.9% from the 52-week high of $41.47 to the low of $17.26 illustrates the potential for significant capital loss.
FAQ
The primary risk is gross margin compression, which dropped from 67.4% to 56.2% YoY, signaling potential cost pressures or competitive pricing. Second, the stock's trailing P/E of 52x leaves it vulnerable to multiple compression if growth disappoints. Third, the stock has been in a sustained downtrend, losing 39% over the past year, and its beta of 0.07 suggests unusual price behavior that may not correlate with the broader market. Fourth, the company relies on acquisitions for growth, as evidenced by $629.5 million in acquisition spending in Q4 2025, which could lead to integration risks and cash flow strain. The most severe risk is a revenue growth deceleration below 15%, which could trigger a re-rating to a forward P/E of 10x, pushing the stock to $17 or lower.
The 12-month outlook is cautiously optimistic. In the bull case (30% probability), revenue growth accelerates to 30%+ and margins expand, driving the stock to $33-$40. In the base case (45% probability), growth remains around 20-25% with modest margin improvement, yielding a target of $28-$33. In the bear case (25% probability), growth decelerates to 15% and margins compress further, pushing the stock to $17-$22. The base case is most likely, supported by the company's strong revenue momentum and analyst consensus. Key assumptions include stable gross margins and continued operating leverage. The average analyst target of $33.46 implies 42.6% upside from the current price of $23.46.
On a trailing basis, Waystar appears overvalued with a P/E of 52.0x, more than double the industry median of 25x. However, on a forward basis, the P/E of 12.7x is well below the industry average of 20x, suggesting the market is pricing in substantial earnings growth. The P/S ratio of 5.7x is also below its historical average of around 20x, indicating the stock is cheaper on a sales basis than in the past. The implied target price based on forward EPS is $33.46, offering 42.6% upside. This dichotomy suggests the stock is undervalued relative to future earnings expectations but overvalued based on current earnings. The market is betting on a sharp earnings ramp, which is aggressive but may be justified by the company's growth trajectory.
Waystar offers a compelling risk/reward for investors who believe in its growth story. The stock trades at a forward P/E of 12.7x, well below the industry average of 20x, and analysts see 42.6% upside to the average target of $33.46. However, the stock has declined 39% over the past year and trades near its 52-week low, indicating significant bearish sentiment. The biggest downside risk is gross margin compression, which fell from 67.4% to 56.2% YoY. For long-term growth investors with a 12-month horizon, it could be a good buy if revenue growth remains above 20% and margins stabilize. For short-term traders, the stock's high volatility and downtrend present risks. Overall, it is a speculative buy given the valuation discount but requires monitoring of margin trends.
Waystar is better suited for a medium- to long-term investment horizon of 12-18 months, given its growth stage and valuation dynamics. The company is in a high-growth phase with 24.4% revenue growth, but its stock has high volatility (beta 0.07 is misleadingly low; actual price swings have been large). The forward P/E of 12.7x suggests near-term upside if earnings materialize, but the trailing P/E of 52x indicates that current earnings are thin. Short-term trading is risky due to the stock's downtrend and low liquidity (only 5 analysts cover it). A minimum holding period of 12 months is recommended to allow the growth story to play out and for earnings to catch up to the valuation. The company does not pay a dividend, so total return depends on price appreciation.
